COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:

Search Results

One moment please while the data are loaded...

The DNTP Technical Report (TR) Level of Evidence Criteria are available here: https://ntp.niehs.nih.gov/go/baresults. In the table below this information is further delineated into three fields:

  • Level of Evidence: The overall category of evidence of carcinogenic activity for the TR, Species, Strain and Sex
  • Organ Site Call: The level of evidence supported by the specific organ site for the TR, Species, Strain and Sex. When the Organ Site Call directly supports the TR Level Of Evidence the Finding Type flag is set to “Neoplastic Lesion”. Some Organ Site Calls could support a separate call of Equivocal Evidence; this is noted in Finding Type by the flag “May Have Been Related”
  • Finding Type: Further identification of the Organ Site Call. Where this says “Neoplastic Lesion” the Organ Site Call supports the TR Level of Evidence and the Organ Site Call is the same as that of the TR. Where Finding Type says “May Have Been Related” the TR Level of Evidence for other responses led to an overall call of Clear or Some Evidence but the specified organ supports a call of Equivocal Evidence.
View results
  • Organ: Uterus
  • Level of Evidence: Positive, Clear Evidence, Some Evidence
Displays results that match exactly with the given criteria.
Exact Match Publication No. CASRN Test Article Name Species Strain Sex Route Organ Level of Evidence Organ Site Call Tumor Type/Incidence Finding Type
Yes TR-559 31508-00-6 Toxic equivalency factor evaluation (PCB 118) Rats Harlan Sprague-Dawley Female Gavage Uterus Clear Evidence Equivocal Evidence Squamous cell carcinoma: 0/52 0/52 3/52 1/52 1/52 0/52 1/50 May Have Been Related
Yes TR-559 31508-00-6 Toxic equivalency factor evaluation (PCB 118) Rats Harlan Sprague-Dawley Female Gavage Uterus Clear Evidence Clear Evidence Carcinoma 2/52 2/52 1/52 3/52 4/52 3/52 11/50 Neoplastic Lesions
Yes TR-561 119-64-2 Tetralin Rats F344/N Female Inhalation Uterus Some Evidence Some Evidence Stromal polyp 6/50 10/50 9/50 17/50 Neoplastic Lesions
Yes TR-576 15625-89-5 Trimethylolpropane triacrylate Mice B6C3F1 Female Topical Application Uterus Some Evidence Some Evidence stromal polyp or stromal sarcoma 0/50, 1/50, 2/50, 6/50 Neoplastic Lesions
Yes TR-589 32534-81-9 Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] Rats Wistar Han Female Gavage Uterus Clear Evidence Equivocal Evidence stromal polyp or stromal sarcoma (original and residual evaluations, combined) 4/50 12/50 12/50 9/49 May Have Been Related
Yes TR-584 700-06-1 Indole-3-carbinol Rats Harlan Sprague-Dawley Female Gavage Uterus Some Evidence Some Evidence adenocarcinoma (standard evaluation) 0/50 1/50 4/50 4/50 (standard and extended evaluations) combined 5/50 4/50 13/50 10/50 Neoplastic Lesions
Yes TR-594 98-56-6 p-Chloro-a,a,a-trifluorotoluene Rats Harlan Sprague-Dawley Female Inhalation Uterus Some Evidence Some Evidence adenocarcinoma (1/50, 1/50, 0/50, 5/50); stromal polyp (7/50, 9/50, 16/50, 12/50) Neoplastic Lesions
Yes TR-598 335-67-1 Perfluorooctanoic acid (PFOA) Rats Harlan Sprague-Dawley Female Dosed-Feed Uterus Some Evidence Equivocal Evidence Perinatal + Postweaning: adenocarcinoma (1/50, 3/50, 5/50) May Have Been Related
Yes TR-598 335-67-1 Perfluorooctanoic acid (PFOA) Rats Harlan Sprague-Dawley Female Dosed-Feed Uterus Some Evidence Equivocal Evidence Postweaning: adenocarcinoma (1/50, 5/50, 8/50) May Have Been Related
Yes TR-587 79-94-7 Tetrabromobisphenol A Rats Wistar Han Female Gavage Uterus Clear Evidence Clear Evidence adenoma (original transverse review) 0/50 0/50 3/50 4/50 adenocarcinoma (original transverse review) 3/50 3/50 8/50 9/50 )original transverse and residual longitudinal reviews, combined) 4/50 10/50 15/50 16/50 malignant mixed Müllerian tumor (original transverse review) 0/50 4/50 0/50 2/50 adenoma, adenocarcinoma, or malignant mixed Müllerian tumor (original transverse review) 3/50 7/50 11/50 13/50 )original transverse and residual longitudinal reviews, combined) 6/50 11/50 16/50 19/50 Neoplastic Lesions